Overexpression of the HER2 protein and/or amplification of the HER2-encoding gene have been associated with an unfavorable prognosis in several types of cancer, including breast, gastric, and pancreatic cancer (17–19). This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.